Asiaticoside treatment for adults with overweight or obesity
A Clinical Efficacy Study of Asiaticoside for Treating Overweight/Obesity
This study will try oral asiaticoside tablets to see if they help adults with overweight or obesity lose weight and improve related metabolic measures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shanghai Zhongshan Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT07241533 on ClinicalTrials.gov |
What this trial studies
This is an exploratory interventional study giving oral asiaticoside tablets to adults with a body mass index (BMI) of 24.0–45.0 kg/m² to examine effects on body weight and metabolic health. The trial is conducted at Zhongshan Hospital, Fudan University, and enrolls consenting adults without major infectious, malignant, severe organ dysfunction, or secondary causes of obesity. Participants receiving asiaticoside will have clinical visits and measurements of weight, body composition, blood lipids, and metabolic markers over the treatment period. The design builds on preclinical mouse studies that reported reduced weight gain, lower adipose tissue mass, improved triglycerides, and better hepatic steatosis and insulin sensitivity with asiaticoside-class compounds.
Who should consider this trial
Good fit: Adults aged 18 years or older with BMI 24.0–45.0 kg/m² who can give written informed consent and do not meet exclusion criteria may be eligible.
Not a fit: People with active severe infections or malignancy, HIV, severe liver or kidney dysfunction, recent major cardiovascular events, severe gastrointestinal disease, secondary causes of obesity, or those currently on other anti-obesity treatments are unlikely to benefit or qualify for this study.
Why it matters
Potential benefit: If successful, asiaticoside could reduce body weight and body fat and improve blood triglycerides, liver fat, and insulin sensitivity in people with overweight or obesity.
How similar studies have performed: Preclinical studies in high-fat diet obese mice showed promising weight and metabolic benefits from asiaticoside-related compounds, but human clinical data are currently limited and this approach remains largely untested in people.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years or older, male or female. * Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m². * Able and willing to provide written informed consent. Exclusion Criteria: * Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other severe infectious or immunocompromising conditions. * Severe liver injury (AST or ALT \> 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR \< 30 mL/min/1.73 m²). * Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months. * Severe gastrointestinal disorders, or a history of gastrointestinal surgery within the past year. * Secondary causes of obesity, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, acromegaly; or drug-induced obesity (e.g., antipsychotics, glucocorticoids). * Currently receiving other anti-obesity treatments, a previous history of bariatric surgery, or a \>5% reduction in body weight within the past 3 months. * Current smoker or habitual smoker within the past 3 months. * type 1 or type 2 diabetes mellitus or currently taking hypoglycemic medications. * Pregnancy or planning pregnancy, or breastfeeding. * Unable to complete a 3-month follow-up due to health conditions or relocation. * Participation in any clinical study within the past 4 weeks. * Other conditions considered by investigators as unsuitable for participation.
Where this trial is running
Shanghai, Shanghai Municipality
- Zhongshan Hospital, Fudan University — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Jingjing JIANG, MD, PhD
- Email: jiang.jingjing@zs-hospital.sh.cn
- Phone: 86-021-64041990
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.